BD² in JAMA Medical News

Bipolar disorder is difficult to both diagnose and treat. The disorder is characterized by a range of symptoms including hypomania and depression that vary from patient to patient, and effective medical treatment is often only found after patients try multiple ineffective treatments.

JAMA Medical News details how BD² is working to better understand the genetic roots and clinical features of bipolar disorder to improve diagnosis and treatment. 

JAMA (Melissa Suran, PhD, MSJ): Treating Bipolar Disorder Is Notoriously Difficult, but Research Underway Could Lead to New Options

“BD² is the first project of its kind for bipolar disorder, “as it brings together cross-disciplinary science under a single umbrella,” according to Cara Altimus, PhD, the managing director of BD² and senior director at the Milken Institute Center for Strategic Philanthropy. “The initiative is funding geneticists, clinicians, brain-imaging experts, molecular biologists, and neuroscientists, all with a focus on understanding bipolar disorder. And data from across the initiative will be brought together in a single platform to facilitate collaboration across the community.””